4D Molecular Therapeutics (FDMT) Competitors $6.16 -0.30 (-4.64%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. SNDX, COGT, EVO, AVDL, PAHC, XERS, CVAC, ELVN, CALT, and COLLShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Syndax Pharmaceuticals (SNDX), Cogent Biosciences (COGT), Evotec (EVO), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Xeris Biopharma (XERS), CureVac (CVAC), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Its Competitors Syndax Pharmaceuticals Cogent Biosciences Evotec Avadel Pharmaceuticals Phibro Animal Health Xeris Biopharma CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) Collegium Pharmaceutical 4D Molecular Therapeutics (NASDAQ:FDMT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Is FDMT or SNDX more profitable? Syndax Pharmaceuticals has a net margin of -428.48% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-594,375.81% -40.15% -36.43% Syndax Pharmaceuticals -428.48%-130.47%-56.12% Which has more risk and volatility, FDMT or SNDX? 4D Molecular Therapeutics has a beta of 2.83, meaning that its stock price is 183% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Does the media prefer FDMT or SNDX? In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 2 mentions for 4D Molecular Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.51 beat 4D Molecular Therapeutics' score of 0.62 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better valuation and earnings, FDMT or SNDX? 4D Molecular Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K7,244.34-$160.87M-$3.53-1.76Syndax Pharmaceuticals$77.93M18.26-$318.76M-$3.89-4.25 Do analysts prefer FDMT or SNDX? 4D Molecular Therapeutics presently has a consensus price target of $30.40, suggesting a potential upside of 389.93%. Syndax Pharmaceuticals has a consensus price target of $38.00, suggesting a potential upside of 130.00%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of FDMT or SNDX? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Summary4D Molecular Therapeutics beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$289.35M$2.80B$5.75B$9.84BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-1.7622.5930.7626.60Price / Sales7,244.34741.32459.33120.41Price / CashN/A177.7737.7659.36Price / Book0.696.2410.036.70Net Income-$160.87M$32.94M$3.27B$265.68M7 Day Performance-9.42%1.17%3.36%3.42%1 Month Performance33.73%1.84%4.58%1.09%1 Year Performance-59.44%11.73%44.38%23.94% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.2887 of 5 stars$6.16-4.6%$30.40+393.5%-58.4%$287.67M$40K-1.75120Gap UpSNDXSyndax Pharmaceuticals3.923 of 5 stars$15.87+0.8%$38.00+139.4%-21.9%$1.36B$77.93M-4.08110Positive NewsCOGTCogent Biosciences3.5177 of 5 stars$12.11+1.9%$18.70+54.4%+24.2%$1.35BN/A-6.8080News CoveragePositive NewsAnalyst ForecastEVOEvotec1.5842 of 5 stars$3.68-2.1%$5.40+46.7%-8.2%$1.34B$862.40M0.004,827AVDLAvadel Pharmaceuticals2.7194 of 5 stars$13.48-1.5%$18.67+38.5%-5.9%$1.33B$169.12M-449.3370News CoveragePAHCPhibro Animal Health3.4388 of 5 stars$31.25+1.9%$24.40-21.9%+52.9%$1.24B$1.19B40.061,940News CoverageEarnings ReportGap UpXERSXeris Biopharma3.4091 of 5 stars$7.36-4.2%$6.58-10.6%+177.4%$1.24B$203.07M-35.05290Positive NewsCVACCureVac4.5611 of 5 stars$5.45-0.5%$6.83+25.4%+64.0%$1.23B$579.18M5.92880Positive NewsEarnings ReportELVNEnliven Therapeutics2.768 of 5 stars$19.75-2.3%$41.20+108.6%-8.3%$1.20BN/A-9.8850CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180COLLCollegium Pharmaceutical2.3117 of 5 stars$38.19+1.2%$42.33+10.8%+2.6%$1.19B$631.45M36.72210Positive News Related Companies and Tools Related Companies SNDX Alternatives COGT Alternatives EVO Alternatives AVDL Alternatives PAHC Alternatives XERS Alternatives CVAC Alternatives ELVN Alternatives CALT Alternatives COLL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access